We are a clinical-stage biopharmaceutical company dedicated to developing innovative medicines for patients living with serious chronic diseases and significant unmet needs. IHL-42X, our drug candidate in a pivotal Phase 2/3 clinical trial for the treatment of obstructive sleep apnea ( OSA ) is an oral fixed-dose combination of dronabinol and acetazolamide designed to act synergistically by tar…
The business is unprofitable at the operating level (-27661.63% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 616.7% YoY with margins expanding 222680.0pp.
ROIC dropped from -144.12% to -148.94%, capital efficiency is deteriorating. Negative free cash flow of -$13M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (FY)
$86K
▲ +616.7% YoY
Net Income (TTM)
-$48M
▼ -154.0% YoY
Op. Margin
-27661.63%
▲ +222680.0pp YoY
ROIC
-33.43%
▼ -4.8pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$18M
▲ +22.3% YoY
Op. Cash Flow (TTM)
-$18M
▲ +21.0% YoY
Net Debt
-$74M
Net Cash Position
Cash & Equiv.
$74M
Continue Research